1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Blushing: new trials by email Literature Review of Blushing trials Research Report on Blushing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
Mastocytosis (1) · Mastocytosis, Systemic (1) · Piebaldism (1) · Pruritus (1)
Albinism (1) · Amino Acid Metabolism, Inborn Errors (1) · Behavior (1) · Communication (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Hypopigmentation (1) · Immune System Diseases (1) · Mast Cell Activation Disorders (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Connective Tissue (1)
masitinib (1)
AB Science (1)
France (1) · Germany (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Cristina Bulai Livideanu, MD, MSc (1)
2016 (1)